Cobra signs agreement with US Naval Medical Research Centre
UK-based Cobra Biomanufacturing has signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Centre of the US Navy to construct and test a vac-cine against malaria, using Cobra's proprietary ORT-VAC oral vaccine delivery technology.
UK-based Cobra Biomanufacturing has signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Centre of the US Navy to construct and test a vac-cine against malaria, using Cobra's proprietary ORT-VAC oral vaccine delivery technology.
Financial terms were not disclosed.
Malaria affects about 300-500 million people per year and is responsible for about 2.7 million deaths annually.
Cobra is already in the course of evaluating the ORT-VAC platform in the development of a vaccine against anthrax and plague with UK Defence Science and Technology Laboratory, Porton Down. Similar technology will be used for this collaboration with the US Navy.